Genzyme appoints new leaders for multiple sclerosis and rare disease businesses
pharmafile | November 14, 2011 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Genzyme
Genzyme, a Sanofi company, has appointed William Sibold as head of multiple sclerosis and Rogério Vivaldi as head of rare diseases.
Both will report to David Meeker, the new president and chief executive of Genzyme, and will join the firm’s executive team.
The MS and rare disease businesses constitute Genzyme’s core focus following its integration with Sanofi earlier this year.
“These appointments are a critical step in launching the new Genzyme,” said David Meeker. “Bill and Rogério are dynamic leaders with the experience, energy, vision and commitment to patients needed to move us forward.”
Bill Sibold has more than 20 years of experience in the biopharmaceutical industry, primarily in commercial operations, and has worked on multiple sclerosis products Avonex and Tysabri.
He spent eight years in positions of increasing responsibility at Biogen Idec where, as senior vice president of US commercial operations, he was responsible for the company’s neurology, oncology and rheumatology therapeutic areas.
Rogério Vivaldi joined Genzyme in 1997 and has held positions of increasing responsibility over his career with the company.
He previously served as senior vice president and president of Genzyme Latin America, responsible for the company’s significant growth and diversification in the region, after founding Genzyme.
Related Content

Use of Genzyme’s MS drug Lemtrada restricted under ongoing EMA safety review
The EMA has launched a review into Genzyme’s multiple sclerosis drug Lemtrada (alemtuzumab) after reports …

Alnylam and Sanofi close research phase of 2014’s $700m RNAi rare disease partnership
Alnylam and Sanofi have announced their intention to bring to an end the research and …

Cancer drugs prices vary up to 388% between high-income countries
The price of new cancer drugs varies widely between high-income countries in Europe, Australia, and …






